Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies

Human adenoviruses (HAdV) are ubiquitous human pathogens that cause a significant burden of respiratory, ocular, and gastrointestinal illnesses. Although HAdV infections are generally self-limiting, pediatric and immunocompromised individuals are at particular risk for developing severe disease. Currently, no approved antiviral therapies specific to HAdV exist. Recent outbreaks underscore the need for effective antiviral agents to treat life-threatening infections. In this review we will focus on recent developments in search of potential therapeutic agents for controlling HAdV infections, with a focus on those targeting post-entry stages of the virus replicative cycle.

Automated summary

Human adenoviruses are common pathogens causing respiratory, ocular, and gastrointestinal illnesses, with severe risks for children and immunocompromised individuals. There are currently no approved antiviral therapies specific to HAdV, highlighting the urgent need for effective agents to treat life-threatening infections. This review focuses on recent developments in search of potential therapeutic agents targeting post-entry stages of the virus replicative cycle.